News from alkermes plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 11, 2023, 07:00 ET Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress

Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual Psych...
Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program

Sep 07, 2023, 07:00 ET Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program

Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on...

Sep 05, 2023, 16:00 ET Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences....

Aug 31, 2023, 07:00 ET Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program

Alkermes plc (Nasdaq: ALKS) today announced the recipients of the 2023 Alkermes Inspiration Grants® program. Grants were awarded to 11 nonprofit...

Aug 30, 2023, 07:00 ET Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to...

Jul 26, 2023, 07:00 ET Alkermes plc Reports Second Quarter 2023 Financial Results

...

Jul 19, 2023, 16:03 ET Alkermes to Report Second Quarter Financial Results on July 26, 2023

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 26, 2023 to...

Jun 29, 2023, 10:50 ET Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders

Alkermes plc (Nasdaq: ALKS) (the Company) today announced that, at the Company's 2023 Annual General Meeting of Shareholders (the Annual Meeting),...

Jun 26, 2023, 07:00 ET Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders

Today, seven of the recently-appointed independent directors of the Board of Directors (the Board) of Alkermes plc (Nasdaq: ALKS) (the Company)...

Jun 21, 2023, 08:00 ET Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote "FOR" All Seven of the Company's Highly Qualified Director Nominees

Alkermes plc (Nasdaq: ALKS) (the Company) today announced that leading proxy advisory firm Glass, Lewis & Co. (Glass Lewis) has recommended that...

Jun 20, 2023, 07:00 ET Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board

Alkermes plc (Nasdaq: ALKS) (the Company) today announced that independent shareholder advisory firm Institutional Shareholder Services (ISS) has...

Jun 13, 2023, 07:00 ET Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

Alkermes plc (Nasdaq: ALKS) (the Company) today issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General...

Jun 08, 2023, 07:00 ET Alkermes Publishes Investor Presentation Detailing Company's Transformation and Value Creation

Alkermes plc (Nasdaq: ALKS) (the Company) today announced that it has filed an investor presentation with the U.S. Securities and Exchange Commission ...

Jun 06, 2023, 06:00 ET Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations

Alkermes plc (Nasdaq: ALKS) today announced that on May 31, 2023 it received a final award (the Final Award) from the arbitral tribunal (the...

Jun 01, 2023, 16:01 ET Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

Alkermes plc (Nasdaq: ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural...

May 31, 2023, 16:00 ET Alkermes to Participate in Two Upcoming Investor Conferences

Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences. Jefferies...

May 25, 2023, 16:15 ET Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

Alkermes plc (Nasdaq: ALKS) (the Company) today filed its definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and...

May 16, 2023, 07:00 ET Alkermes Highlights Data From Psychiatry Portfolio at Spring 2023 Scientific Conferences

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry portfolio—which includes LYBALVI® (olanzapine and...

May 09, 2023, 07:00 ET Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel,...

May 08, 2023, 16:41 ET Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process

Alkermes plc (Nasdaq: ALKS) today filed its preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with its ...

Apr 26, 2023, 07:00 ET Alkermes plc Reports First Quarter 2023 Financial Results

...

Apr 25, 2023, 07:00 ET Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

Alkermes plc (Nasdaq: ALKS) today announced that on April 19, 2023 it received a second interim award (the "Second Interim Award") from the arbitral...

Apr 19, 2023, 16:00 ET Alkermes to Report First Quarter Financial Results on April 26, 2023

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, April 26, 2023 to...

Apr 19, 2023, 07:00 ET Alkermes Announces Application Period for 2023 Alkermes Inspiration Grants® Program to Support Innovative Initiatives Focused on People Affected by Addiction, Serious Mental Illness or Cancer

Alkermes plc (Nasdaq: ALKS) today announced that the company will accept applications for its Alkermes Inspiration Grants® program beginning on May...

Apr 18, 2023, 07:00 ET Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business

Alkermes plc (Nasdaq: ALKS) today announced that it has submitted a confidential draft Form 10 registration statement to the United States Securities ...